Comparison of Repeated Doses of Ivermectin Versus Ivermectin Plus Albendazole for the Treatment of Onchocerciasis: A Randomized, Open-label, Clinical Trial.
albendazole
ivermectin
onchocerciasis
semiannual treatment
therapy
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
14 08 2020
14 08 2020
Historique:
received:
23
04
2019
accepted:
13
09
2019
pubmed:
20
9
2019
medline:
28
4
2021
entrez:
20
9
2019
Statut:
ppublish
Résumé
Improved treatment for onchocerciasis is needed to accelerate onchocerciasis elimination in Africa. Aiming to better exploit registered drugs, this study was undertaken to determine whether annual or semiannual treatment with ivermectin (IVM; 200 µg/kg) plus albendazole (ALB; 800 mg single dose) is superior to IVM alone. This trial was performed in Ghana and included 272 participants with microfilariae (MF), who were randomly assigned to 4 treatment arms: (1) IVM annually at 0, 12, and 24 months; (2) IVM semiannually at 0, 6, 12, 18, and 24 months; (3) IVM+ALB annually; or (4) IVM+ALB semiannually. Microfiladermia was determined pretreatment and at 6, 18, and 36 months. The primary outcome was the proportion of fertile and viable female worms in onchocercomata excised at 36 months. Posttreatment nodule histology showed that 15/135 (11.1%), 22/155 (14.2%), 35/154 (22.7%), and 20/125 (16.0%) living female worms had normal embryogenesis in the IVM annual, IVM semiannual, IVM+ALB annual, and IVM+ALB semiannual groups, respectively (P = .1229). Proportions of dead worms also did not differ between the 4 groups (P = .9198). Proportions of patients without MF at 36 months (1 year after the last treatment) were 35/56 (63%) after annual IVM, 42/59 (71%) after semiannual IVM, 39/64 (61%) after annual IVM+ALB, and 43/53 (81%) after semiannual IVM+ALB. The combination treatment of IVM plus ALB was no better than IVM alone for sterilizing, killing adult worms, or achieving sustained MF clearance. However, semiannual treatment was superior to annual treatment for achieving sustained clearance of Onchocerca volvulus MF from the skin (P = .024). ISRCTN50035143.
Sections du résumé
BACKGROUND
Improved treatment for onchocerciasis is needed to accelerate onchocerciasis elimination in Africa. Aiming to better exploit registered drugs, this study was undertaken to determine whether annual or semiannual treatment with ivermectin (IVM; 200 µg/kg) plus albendazole (ALB; 800 mg single dose) is superior to IVM alone.
METHODS
This trial was performed in Ghana and included 272 participants with microfilariae (MF), who were randomly assigned to 4 treatment arms: (1) IVM annually at 0, 12, and 24 months; (2) IVM semiannually at 0, 6, 12, 18, and 24 months; (3) IVM+ALB annually; or (4) IVM+ALB semiannually. Microfiladermia was determined pretreatment and at 6, 18, and 36 months. The primary outcome was the proportion of fertile and viable female worms in onchocercomata excised at 36 months.
RESULTS
Posttreatment nodule histology showed that 15/135 (11.1%), 22/155 (14.2%), 35/154 (22.7%), and 20/125 (16.0%) living female worms had normal embryogenesis in the IVM annual, IVM semiannual, IVM+ALB annual, and IVM+ALB semiannual groups, respectively (P = .1229). Proportions of dead worms also did not differ between the 4 groups (P = .9198). Proportions of patients without MF at 36 months (1 year after the last treatment) were 35/56 (63%) after annual IVM, 42/59 (71%) after semiannual IVM, 39/64 (61%) after annual IVM+ALB, and 43/53 (81%) after semiannual IVM+ALB.
CONCLUSIONS
The combination treatment of IVM plus ALB was no better than IVM alone for sterilizing, killing adult worms, or achieving sustained MF clearance. However, semiannual treatment was superior to annual treatment for achieving sustained clearance of Onchocerca volvulus MF from the skin (P = .024).
CLINICAL TRIALS REGISTRATION
ISRCTN50035143.
Identifiants
pubmed: 31536624
pii: 5571844
doi: 10.1093/cid/ciz889
pmc: PMC7428389
doi:
Substances chimiques
Ivermectin
70288-86-7
Albendazole
F4216019LN
Banques de données
ISRCTN
['ISRCTN50035143']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
933-943Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lancet Infect Dis. 2013 Nov;13(11):922-3
pubmed: 24319775
Acta Trop. 1993 Jan;52(4):221-66
pubmed: 8094587
Clin Infect Dis. 2014 Oct;59(7):923-32
pubmed: 24944228
Parasitol Res. 2009 Dec;106(1):23-31
pubmed: 19756742
Trans R Soc Trop Med Hyg. 1998 Jan-Feb;92(1):94-7
pubmed: 9692166
Lancet Infect Dis. 2008 May;8(5):310-22
pubmed: 18471776
Med Microbiol Immunol. 2008 Sep;197(3):295-311
pubmed: 17999080
PLoS Med. 2006 Sep;3(9):e371
pubmed: 17002504
Trans R Soc Trop Med Hyg. 2001 May-Jun;95(3):332-5
pubmed: 11491010
Ann Trop Med Parasitol. 2003 Mar;97(2):165-78
pubmed: 12803872
Parasitol Res. 2009 Nov;105(6):1531-8
pubmed: 19784672
Lancet. 2018 Oct 6;392(10154):1207-1216
pubmed: 29361335
Epidemics. 2017 Mar;18:4-15
pubmed: 28279455
PLoS One. 2014 Dec 29;9(12):e115886
pubmed: 25545677
Trop Med Parasitol. 1995 Dec;46(4):213-20
pubmed: 8826100
Parasit Vectors. 2015 Mar 19;8:167
pubmed: 25889256
PLoS Negl Trop Dis. 2017 Jan 5;11(1):e0005156
pubmed: 28056021
Trop Med Parasitol. 1991 Dec;42(4):356-60
pubmed: 1796233
Filaria J. 2005 Mar 23;4(1):1
pubmed: 15788103
Lancet Infect Dis. 2014 May;14(5):373-4
pubmed: 24758997
PLoS Negl Trop Dis. 2014 Jun 26;8(6):e2953
pubmed: 24968000
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16716-21
pubmed: 19805362
Parasitol Res. 2009 Jan;104(2):437-47
pubmed: 18850111
PLoS Negl Trop Dis. 2015 Sep 11;9(9):e0004056
pubmed: 26360917
Int Health. 2016 Mar;8 Suppl 1:i28-33
pubmed: 26940307
Microbes Infect. 2003 Apr;5(4):261-73
pubmed: 12706439